RT Journal Article
SR Electronic
T1 Genomic epidemiology identifies emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.06.21251159
DO 10.1101/2021.02.06.21251159
A1 Washington, Nicole L.
A1 Gangavarapu, Karthik
A1 Zeller, Mark
A1 Bolze, Alexandre
A1 Cirulli, Elizabeth T.
A1 Barrett, Kelly M. Schiabor
A1 Larsen, Brendan B.
A1 Anderson, Catelyn
A1 White, Simon
A1 Cassens, Tyler
A1 Jacobs, Sharoni
A1 Levan, Geraint
A1 Nguyen, Jason
A1 Ramirez, Jimmy M.
A1 Rivera-Garcia, Charlotte
A1 Sandoval, Efren
A1 Wang, Xueqing
A1 Wong, David
A1 Spencer, Emily
A1 Robles-Sikisaka, Refugio
A1 Kurzban, Ezra
A1 Hughes, Laura D.
A1 Deng, Xianding
A1 Wang, Candace
A1 Servellita, Venice
A1 Valentine, Holly
A1 De Hoff, Peter
A1 Seaver, Phoebe
A1 Sathe, Shashank
A1 Gietzen, Kimberly
A1 Sickler, Brad
A1 Antico, Jay
A1 Hoon, Kelly
A1 Liu, Jingtao
A1 Harding, Aaron
A1 Bakhtar, Omid
A1 Basler, Tracy
A1 Austin, Brett
A1 Isaksson, Magnus
A1 Febbo, Phillip G.
A1 Becker, David
A1 Laurent, Marc
A1 McDonald, Eric
A1 Yeo, Gene W.
A1 Knight, Rob
A1 Laurent, Louise C.
A1 de Feo, Eileen
A1 Worobey, Michael
A1 Chiu, Charles
A1 Suchard, Marc A.
A1 Lu, James T.
A1 Lee, William
A1 Andersen, Kristian G.
YR 2021
UL http://medrxiv.org/content/early/2021/02/07/2021.02.06.21251159.abstract
AB As of January of 2021, the highly transmissible B.1.1.7 variant of SARS-CoV-2, which was first identified in the United Kingdom (U.K.), has gained a strong foothold across the world. Because of the sudden and rapid rise of B.1.1.7, we investigated the prevalence and growth dynamics of this variant in the United States (U.S.), tracking it back to its early emergence and onward local transmission. We found that the RT-qPCR testing anomaly of S gene target failure (SGTF), first observed in the U.K., was a reliable proxy for B.1.1.7 detection. We sequenced 212 B.1.1.7 SARS-CoV-2 genomes collected from testing facilities in the U.S. from December 2020 to January 2021. We found that while the fraction of B.1.1.7 among SGTF samples varied by state, detection of the variant increased at a logistic rate similar to those observed elsewhere, with a doubling rate of a little over a week and an increased transmission rate of 35-45%. By performing time-aware Bayesian phylodynamic analyses, we revealed several independent introductions of B.1.1.7 into the U.S. as early as late November 2020, with onward community transmission enabling the variant to spread to at least 30 states as of January 2021. Our study shows that the U.S. is on a similar trajectory as other countries where B.1.1.7 rapidly became the dominant SARS-CoV-2 variant, requiring immediate and decisive action to minimize COVID-19 morbidity and mortality.Competing Interest StatementNLW, AB, ETC, KMSB, SW, CRG, ES, TC, XW, JN, JMR, GL, DW, DB, ML, MI, SJ, JTL, and WL are employees of Helix. KG, BS, JA, KH, JL, EdF, and PGF are employees of Illumina. JN, CRG, ML own stock in ILMN.Funding StatementThis work has been funded by CDC BAA contracts 75D30121P10258 (Illumina, Helix) and 75D30120C09795 (GWY, RK, LCL, KGA), NIH NIAID 3U19AI135995-03S2 (MAS, KGA), U19AI135995 (MAS, KGA), U01AI151812 (KGA), NIH NCATS UL1TR002550 (KGA), the Innovative Genomics Institute (CYC), and the New Frontiers in Research Fund provided by the Canadian Institutes of Health Research (CYC).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Helix data analyzed and presented here were obtained through IRB protocol WIRB#20203438, which grants a waiver of consent for a limited dataset for the purposes of public health under section 164.512(b) of the Privacy Rule (45 CFR 164.512(b)). This work was also evaluated and approved by the Institutional Review Board at The Scripps Research Institute under IRB protocol IRB-15-6664. The work was conducted under a waiver of consent and received a non-human subjects research designation (category 4 exemption) because this research was performed with remnant clinical diagnostic specimens. All samples were de-identified before receipt by the study investigators.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data and processing scripts are available at https://github.com/andersen-lab/paper_2021_early-b117-usa; Viral sequences have been deposited at GISAID, with accession numbers as listed in Supplemental Tables.; Additionally, continuing monitoring of the phenomena described in the manuscript can be found at https://www.helix.com/covid19db https://github.com/andersen-lab/paper_2021_early-b117-usa https://www.helix.com/covid19db